Skip Navigation
Find a Doctor


Photo of Dr. Kieren Marr

Kieren Marr, MD

Director, Transplant and Oncology Infectious Diseases
Professor of Medicine
Appointment Phone


Main Location

The Johns Hopkins Hospital

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Director, Transplant and Oncology Infectious Diseases
  • Professor of Medicine
  • Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center


Infection Management in Compromised Hosts, Infections in Organ Transplants, Infectious Disease, Infectious Diseases, Invasive Fungal Infections

Research Interests

Antimicrobial development and clinical trials; Diagnosis and management of invasive fungal infections; Prevention and treatment of infections in medically immunosuppressed patients


The TOID Program’s Medical Director is Dr. Kieren Marr, Professor of Medicine and Oncology. Dr. Marr trained at Hahnemann University, Duke University and the University of Washington / Fred Hutchinson Cancer Research Center, where she was on faculty for 13 years prior to relocation to Johns Hopkins in 2008. Dr. Marr is a member of several national and international professional organizations, numerous national scientific steering committees, has authored over 150 peer-reviewed publications and textbook chapters, and edited two books in the area of infectious diseases involving immunosuppressed hosts. She is an elected member of the American Society for Clinical Investigators (ASCI) and is known worldwide for her translational and clinical research focused on diagnostics and treatment of invasive fungal infections. Her research has led to establishment of a JHU start-up company, MycoMed Technologies, focused on development of devices and drugs to enable strategies to prevent fungal infections in medically immunosuppressed people. She has an active academic interest in medical research innovation and commercialization and holds a co-appointment in the Carey School of Business. Dr. Marr sees patients and is active in clinical teaching as part of the Barker Firm faculty in the Department of Medicine, and the Transplant and Oncology Infectious Diseases inpatient and outpatient teams.


  • English


Dr. Marr serves on editorial boards for Antimicrobial Agents and Chemotherapy, Clinical Microbiology Reviews, Current Infectious Diseases Reports, and is a section editor for Up to Date in ID. She serves on several advisory bodies, including those developing treatment guidelines by IDSA, the American Thoracic Society, American Society for Blood and Marrow Transplantation, and the National Comprehensive Cancer Network.

1998-current American Society for Microbiology
1999-current International Immunocompromised Host Society
1999-current Infectious Disease Society of America
1999-current International Society for Human and Animal Mycology
2000-current Medical Mycology Society of the Americas
2008- current American Transplant Society
2009-current American Society for Clinical Investigation

Clinical Trial Keywords

  • Antimicrobial
  • Infection

Additional Resources

Additional Resources +
  • Education +


    • Hahnemann University School of Medicine (Philadelphia PA ) (1993)


    • Duke University School of Medicine / Internal Medicine (Durham NC ) (1996)


    • University of Washington Medical Center / Infectious Diseases (Seattle WA ) (1998)


    • Infectious Disease, American Board of Internal Medicine (2009)
  • Research & Publications +

    Selected Publications

    Research Summary

    Antimicrobial development and clinical trials
    Diagnosis and management of invasive fungal infections
    Prevention and treatment of infections in medically immunosuppressed patients

    Journal Citations

    Marr, K.A. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol. 2009 Dec 16.

    Marr, K.A.; Bow, E.; Chiller, T.; Maschmeyer, G.; Ribaud, P.; Segal, B.; Steinbach, W.; Wingard, J.R.; Nucci, M. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Oct;44(8):483-487.

    Neofytos, D.; Horn, D.; Anaissie, E.; Steinbach, W.; Olyaei, A.; Fishman, J.; Pfaller, M.; Chang, C.; Webster, K.; Marr, K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009 Feb 1;48(3):265-273.

    Staab, J.F.; Balajee, S.A.; Marr, K.A. Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism. J Clin Microbiol. 2009 Jul;47(7):2079-2083.

    Chaudhary, N.; Staab, J.F.; Marr, K.A. Healthy human T-Cell Responses to Aspergillus fumigatus antigens. PLoS One. 2010;5(2):e9036.

    Marr, K.A. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol. 2010 Mar;22(2):138-142.

    Marr, K.A.; Subramanian, A.K. Transplantation represents one of the true modern advances in medicine, presenting new and effective treatments for organ and bone marrow failure and neoplastic disorders. Preface. Infect Dis Clin North Am. 2010 Jun;24(2):xiii-v.

    Staab, J.F.; Kahn, J.N.; Marr, K.A. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother. 2010 Dec;54(12):4992-4998.

    Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MED, Corey L, Boeckh M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo controlled trial. Blood. 2000; 96 (6):2055.

    Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother. 2001. 46(1): 52.

    Marr KA, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients Clin Infect Dis. 2002; 34:909-17.

    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern W, Marr KA, Ribaud P, Lortholary O, Sylvester R, de Pauw B. Randomized comparison of voriconazole and amphotericin B in primary therpay of invasive aspergillosis. A collaborative study of the EORTC invasive fungal infection group and the global aspergillosis study group. New Engl J Med. 2002; 347:408-15.

    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risks. Blood. 2002; 10(13):4358-66.

    Fukuda T, Boeckh M, Carter R, Sandmaier B, Maris M, Maloney D, Martin P, Storb R, Marr KA. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: risks and outcomes. Blood. 2003; 102:827-33.

    Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee A, Musher B, Corey L. Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT patients. Blood. 2004; 103: 1527-33.

    Marr KA, Balajee SA, Leisenring W, Weaver B, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of aspergillosis: Variables that affect performance. J Infect Dis. 2004; 190:641-9.

    Musher B, Fredricks D, Leisenring W, Balajee SA, Marr KA. Aspergillus galactomannan EIA and quantitative PCR for diagnosis of aspergillosis in HCT patients using bronchoalveolar lavage. J Clin Microbiol. 2004; 42(12): 5517-22.

    Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov: a new sibling species of A. fumigatus. Eukaryotic Cell. 2005; 4: 625-632.

    Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Platelia Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005; 40(12):1762-9.

    Gersuk GM, Underhill DM, Zhu L, Marr KA. Dectin-1 and Toll-like receptors permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunology. 2006; 176:3717-24.

    Balajee SA, Nickle D, Varga J, Marr KA. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping . Euk Cell. 2006; 5:1705-1712.

    Upton A, Kirby K, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007; 44(4): 531-40.

    Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, Marr KA. First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence of spread of the Vancouver Island outbreak. J Clin Microbiol. 2007; 45(9): 3086-8.

    Bretz C, Gersuk G, Knoblaugh S, Chaudhary N, Randolph-Habecker J, Hackman R, Staab J, Marr KA. MyD88-signaling contributes to early pulmonary responses to Aspergillus fumigatus. Infect Immun. 2008; 76(3): 952-8.

    Zaas AK, Liao G, Chien JW, Weinberg C, Shore D, Giles SS, Marr KA, Usuka J, Burch L, Perera L, Perfect JR, Peltz G, Schwartz DA. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLos Genetics 2008 4(6):e1000101.

    Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mould infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplant. Clin Infect Dis 2008; 47(8): 1041-50.

    Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, Rodrigues SD, Li S, Hansen JA, Zhao LP, Aderem A, Boeckh M. Association of donor Toll-like Receptor 4 polymorphisms with susceptibility to invasive aspergillosis in hematopoietic cell transplant recipients. New Eng J Med 2008; 359(17): 1766-77.

    Byrnes EJ, Bildfell R, Frank SA, Mitchell TG, Marr KA and Heitman J. Molecular evidence that the Vancouver Island Cryptococcus gattii outbreak has expanded into the United States Pacific Northwest. J Infect Dis 2009; 199(7): 1081-6.

    Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, and Marr KA. Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: analysis of multicenter PATH alliance registry. Clin Infect Dis 2009; 48(3): 265-73.

    Mielcarek M, Storer BE, Boeckh MJ, Carpenter PA, McDonald GB, Deeg J, Nash RA, Flowers MED, Doney K, Lee S, Marr KA, Furlong T, Storb R, Appelbaum FR, Martin PJ. Initial therapy of acute graft-vs.-host disease with low dose prednisone does not compromise patient outcomes. Blood 2009; 113(13):2888-94.

    Datta K, Bartlett K, Baer R, Byrnes E, Galanis E, Heitman J, Hoang L, Leslie M, MacDougall L, Morshed M, and Marr KA. Spread of Cryptococcus gattii into Pacific Northwest Region of the United States. Emerg Infect Dis 2009; 176532.

    Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, Andes D, Kontoyiannnis DP, Perrone G, Peterson S, Brandt ME, Pappas PG, and Chiller T. Molecular identification of Aspergillus species: Transplant Associated Infection Surveillance Network (TRANSNET). J Clin Microbiol 2009; 47(10): 3138-41.

    Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MC, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, and Pappas PG. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the TRANSNET database. Clin Infect Dis 2010; 50: 1091-1100.

    Chaudhary N, Staab J, Marr KA. Healthy human T cell responses to recombinant Aspergillus antigens. PLoS One 2010: 5(2): e9036.

    Panackal AA, Li H, Kontoyiannis DP, Mori M, Perego CA, Boeckh M, Marr KA. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010; 50(12): 1588-97.

  • Academic Affiliations & Courses +
  • Activities & Honors +


    Dr. Marr is well published, has written chapters in, and served as Editor for several books. Active in research and research training, Dr. Marr has been the principal investigator for several antimicrobial clinical trials. She has won numerous awards, most recently, membership to the American Society for Clinical Investigation.

    Vice-president, Omicron Theta Epsilon Biological Honors Society (1987); Cancer Federation Scholarship (1988); Laughlin Scholarship (1992); Measy Scholarship (1993) American Medical Womens Association Janet Glasgow Memorial Citation (1993); Alpha Omega Alpha, member (1993); Hahnemann Club Award (1993); Hahnemann Hospital Association Award (1993); NIH loan repayment program recipient (1998, 2002); The Johns Hopkins University Mosaic Leadership Award (2008); American Society for Clinical Investigation (2009)

    Professional Activities

    Assistant Chief Resident, Internal Medicine, Duke University Medical Center, Durham, NC (1996); Editorial board: Antimicrobial Agents and Chemotherapy, Clinical Microbiology Reviews (2000-current); Section editor, Up-to-Date in Infectious Diseases (2002-current); Faculty contributor, Faculty of 1000 (2007-current); Steering group member, NIH Bacteriology and Mycoses Study Group Cancer/BMT section (2002-2004); Program Committee, Infectious Diseases Society of America (2001-2004); Member of Executive Council, Immunocompromised Host Society (2002-2006); Member of fungal infections treatment guideline committee, American Thoracic Society (2006-current); Chair, Fungal Infection Working Group, American Society for Blood and Marrow Transplantation (2008); Ad hoc Reviewer for NIH special interests study sections (ZAI1 HSD-M (M2) and GLM-M and Special Emphasis Panel/Initial Review Group (ZRG1 IDM-N), Innate Immunity program project review (ZAI1-GLM-M-S1), Special Emphasis Panel ZRG1-IDM-N-90S, IDM-M, AZI1 MP-1, AOIC, (2004 current); Standing committee member, NIH NIAID DDR study section (2005 2009)
  • Videos & Media +
  • Events +
  • Contact & Locations +


    The Johns Hopkins Hospital
    600 N. Wolfe Street
    Sheikh Zayed Tower
    Baltimore, MD 21287
    Phone: 443-287-6217
    Appointment Phone: 410-287-6217
    Fax: 410-614-0714
    Location Map
    Johns Hopkins Rockland Physician Practice and Research Group
    10751 Falls Road
    Falls Concourse
    Lutherville, MD 21093
    Phone: 443-287-6217
    Appointment Phone: 443-287-6217
    Fax: 410-614-0714
    Location Map


    • Medicine - Infectious Diseases

Is This You? Edit Profile


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.